Robert Damoiseaux

Robert Damoiseaux, Ph.D. is a High Throughput Screening (HTS) expert and a professor in the Department of Molecular and Medical Pharmacology of the David Geffen School of Medicine and Professor of Bioengineering in the Samueli School of Engineering at UCLA. His research interests focus on the development of novel technologies for HTS and Drug Discovery and Development. He also directs the Molecular Screening Shared Resource (MSSR) which is a cutting edge facility involved in research projects with, among others, UCLA, Caltech, and the biotech and pharmaceutical industries. He received his PhD at the University of Lausanne under Dr. Kai Johnsson (currently Director at the Max Planck Institute for Medical Research, Munich) and then joined the Institute for Functional Genomics (GNF, Novartis) where he was in charge of the development of the next generation assay platform for proteases. He authored over 100 manuscripts and patents on high throughput screening and synthesis, was recognized as expert author in Wiley’s Development of Therapeutic Agents Handbook and is also an editor for Springers Current Protocols in Molecular biology. He is also member of the NIH study section and special emphasis panel reviewing high throughput screening grants. His expertise in high-through-put screening and the use of novel technologies brings him into demand for scientific collaborations and consulting for both academia and industry.